Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment

From the Mayo Clinic College of Medicine, Rochester, Minn. (R.C.P.); University of California, San Diego, San Diego (R.G.T., D.G., S.J., L.J.T.); Elan Pharmaceuticals, San Diego (M.G.); Rush University Medical School, Chicago (D.B.); Baylor College of Medicine, Houston (R.D.); New York University, New York (S.F.); Oregon Health and Science University, Portland (J.K.); Emory University, Atlanta (A.L.); University of South Florida, Tampa (E.P.); Mt. Sinai School of Medicine, New York (M.S.); and Yale University, New Haven, Conn. (C.H.D.). Address reprint requests to Dr. Petersen at the Alzheimer’s Disease Research Center, Mayo Clinic College of Medicine, 200 First St. SW, Rochester, MN 55905, or at peter8@mayo. edu. *Members of the Alzheimer’s Disease Cooperative Study (ADCS) Group are listed in the Appendix. This article was published at www.nejm. org on April 13, 2005. N Engl J Med 2005;352:2379-88. Copyright © 2005 Massachusetts Medical Society. background Mild cognitive impairment is a transitional state between the cognitive changes of normal aging and early Alzheimer’s disease.